ALS News & Analysis
2 articles
Market Mood
BrainStorm (BCLI) appoints ex-FDA official before ALS trial
BrainStorm Cell Therapeutics (BCLI) has appointed a former FDA official to its board in preparation for an upcoming trial focused on amyotrophic lateral sclerosis (ALS). This strategic move is aimed at strengthening the company's regulatory compliance and enhancing its clinical trial processes. The trial's success would be significant in advancing BrainStorm's product pipeline and could impact investor confidence and market valuation. The exact timeline for the trial was not disclosed, but such appointments often indicate proactive leadership in navigating regulatory challenges.
Read More
AB Science (AB) Reports Survival Data for ALS Drug Masitinib
AB Science (AB) released new survival data regarding its drug masitinib for ALS treatment. The reported data suggests a potential improvement in patient outcomes, though specific figures related to survival rates were not disclosed in this announcement. This development could influence the company's stock price and investor interest, particularly if further clinical trial results support these findings. The ALS drug market is competitive, and advancements in treatment options may significantly impact AB's market position.
Read More